Skip to main content
Fig. 7 | Molecular Cancer

Fig. 7

From: Hsa_circ_0136666 stimulates gastric cancer progression and tumor immune escape by regulating the miR-375/PRKDC Axis and PD-L1 phosphorylation

Fig. 7

Hsa_circ_0136666 is a novel drug target that siRNA can effectively improve anti-PD-L1 drug efficacy (a) Schematic diagram of animal dosage. 14 days after tumor inoculation, mice were injected with LNP-siRNA at a dose of 2 mg/kg intratumorally, and 2 mg/kg mouse PD-L1 inhibitor was injected intraperitoneally the next day. The dosing cycle was three days for five times. b QRT-PCR was used to detect the knockdown efficiency of siRNA, n = 3. c Original photo of tumor in tumor bearing mice under LNP and inhibitor treatment. d Body weight curve of tumor bearing mice, n = 6. e Tumor growth curve of tumor bearing mice, n = 6. f Comparison of tumor weight in mice, n = 6. g Distribution difference and quantitative analysis of immunosuppressive cells in tumor area of tumor bearing mice among groups, n = 6. **P < 0.01, ***P < 0.001, ****P < 0.0001

Back to article page

Molecular Cancer

ISSN: 1476-4598